Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2022.0313


Genome and transcriptome-based development of new biomarkers and drugs.

William CS CHO, MD, PhD.


Large-scale projects integrating whole exome sequencing (WES), whole genome sequencing (WGS), and RNA sequencing (RNA-seq) have highlighted the new era of Cancer Precision Medicine. These studies have substantially expanded the cancer genes and targets catalogues. Moreover, intratumor heterogeneity and circulating cell-free DNA or tumor DNA (cfDNA, ctDNA) profiling with next generation sequencing are emerging as novel robust biomarkers to guide individualized meaningful treatment. In this review potential and challenges in the translation of these advances into cancer clinical care are discussed.

(Citation: Gastric & Breast Cancer 2022; 17(1): 34-40)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 13 January 2022